The Zhitong Finance App learned that recently, Flare Therapeutics announced that it has reached a strategic discovery cooperation with Roche (RHHBY.US). The collaboration will use Flare Therapeutics' proteomics and mass spectrometry platforms and its proprietary library of electrophilic compounds to discover novel small molecule drugs to target undeveloped transcription factor targets in oncology. As part of the partnership, Flare Therapeutics will receive an advance payment of $70 million and be eligible for discovery, development, and commercialization milestones that could exceed $1.8 billion.

In the collaborative project, Flare Therapeutics will lead the discovery and pre-clinical activities of multiple transcription factor targets in oncology, while Roche will use its expertise in oncology to further develop pre-clinical, clinical development and commercialization activities for potential products in the partnership.

According to reports, Flare Therapeutics is a biotechnology company focused on developing drugs that target transcription factors. Since its inception, Flare Therapeutics has rapidly established its pipeline of emerging projects, including its flagship project, FX-909, an oral small molecule inhibitor targeting PPARG and potentially “first-in-class”. PPARG is the main regulator of advanced urothelial carcinoma lumen lineage cells. FX-909 is currently undergoing phase 1 research.